Remarks

Prior to this filing, claims 1, 6-11, 13-18, 21, 26-28, 32-34, and 38-45 were pending in this application. Claims 1, 6-11, 13-18, 21, 26-28, 32-34, and 38 are canceled herein without prejudice.

After entry of this amendment, **claims 39-45 are pending**. Applicants reserve the right to pursue any removed subject matter in a related application. This filing is proper after final rejection because it cancels non-allowed claims and places the application in condition for allowance.

Withdrawal of Rejections/Allowance of Claims

Applicants thank Examiner Huff for stating in the Advisory action dated July 25, 2008 that the rejection of claims 39-45 under 35 U.S.C. §112, first paragraph (enablement) has been withdrawn and that claims 39-45 are allowable.

Claim Rejections Under 35 U.S.C. §103

Dasch et al. in view of Barbera-Guillem and Rosenblum

Claims 1, 6-9, 11, 13-15, 21, 26-28, 32-34, and 38 continue to be rejected under 35 U.S.C. §103 as obvious over Dasch *et al.* (U.S. Patent No. 6,090,383) in view of Barbera-Guillem (U.S. Patent No. 6,224,866) and Rosenblum (U.S. Patent Application No. 2005/0214307). Applicants traverse this rejection. However, solely to advance prosecution in this case, claims 1, 6-9, 11, 13-15, 21, 26-28, 32-34, and 38 are canceled herein, rendering the rejection of these claims moot.

Dasch et al. in view of Barbera-Guillem, Rosenblum, and Suthanthiran et al.

Claims 1, 6-11, 13-15, 21, 26-28, 32-34, and 38 continue to be rejected under 35 U.S.C. §103 as allegedly being unpatentable over Dasch *et al.* in view of Barbera-Guillem, Rosenblum, and Suthanthiran *et al.* (U.S. Publication No. US 2004-0197333). Applicants respectfully traverse this rejection. However, solely to advance prosecution in this case, claims 1, 6-11, 13-15, 21, 26-28, 32-34, and 38 are canceled herein, rendering the rejection of these claims moot.

Dasch et al. in view of Barbera-Guillem, Rosenblum, and Terabe et al.

Claims 1, 6-9, 11, 13-18, 21, 26-28, 32-34, and 38 continue to be rejected under 35 U.S.C. §103 as allegedly being unpatentable over Dasch et al. in view of Barbera-Guillem, Rosenblum, and AC/TMH:clh1 08/12/08 963019 E-289-2002/0-US-03

Terabe *et al.* (*Nature Immunology*, 1:515-520, 2000). Applicants respectfully traverse this rejection. However, solely to advance prosecution in this case, claims 1, 6-9, 11, 13-18, 21, 26-28, 32-34, and 38 are canceled herein, rendering the rejection of these claims moot.

In light of the above amendments, Applicants respectfully request that the rejections of claims 1, 6-11, 13-18, 21, 26-28, 32-34, and 38 be withdrawn.

Conclusion

Based on the foregoing amendments, the pending claims are in condition for allowance and notification to this effect is requested. If for any reason the Examiner believes that a telephone conference would expedite allowance of the claims, please telephone the undersigned at the number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301 By /Anne Carlson/
Anne Carlson, Ph.D.
Registration No. 47,472